{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:49:12Z","timestamp":1785894552463,"version":"3.56.0"},"reference-count":71,"publisher":"Walter de Gruyter GmbH","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Parathyroid hormone (PTH) determination is of paramount importance for the exploration of diseases related with calcium metabolism and for the follow-up of patients suffering from bone and mineral disorders associated with chronic kidney diseases (CKD-MBD). Unfortunately, the biologically active form of PTH, i.e. 1\u201384\u00a0PTH, circulates in the blood stream with many fragments and post-translationally modified forms, which decreases the specificity of immunoassays. The assays used to measure PTH, either from 2nd or 3rd generation, are not standardised, which may lead to interpretation errors and clinical consequences. Reference ranges for PTH have neither been always correctly established and the stability of the peptide is also a matter of concern. Fortunately, these last years, newer techniques using mass spectrometry (either high resolution or triple quadripole) coupled with liquid chromatography have been developed, which will help to standardise the different assays. Indeed, PTH assays standardisation is one of the task of the IFCC Committee for Bone Metabolism. Such standardisation will allow a better consistency in the interpretation of the results and will promote studies aiming at the establishment of correct reference ranges.<\/jats:p>","DOI":"10.1515\/cclm-2022-0942","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T21:32:36Z","timestamp":1673731956000},"page":"946-953","source":"Crossref","is-referenced-by-count":15,"title":["Determination of parathyroid hormone: from radioimmunoassay to LCMS\/MS"],"prefix":"10.1515","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-2226","authenticated-orcid":false,"given":"Etienne","family":"Cavalier","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, CHU de Li\u00e8ge, CIRM , University of Liege , Li\u00e8ge , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"key":"2023040601553319975_j_cclm-2022-0942_ref_001","doi-asserted-by":"crossref","unstructured":"Ramasamy, I. Inherited disorders of calcium homeostasis. Clin Chim Acta 2008;394:22\u201341. https:\/\/doi.org\/10.1016\/J.CCA.2008.04.011.","DOI":"10.1016\/j.cca.2008.04.011"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_002","doi-asserted-by":"crossref","unstructured":"J\u00fcppner, H, Abou-Samra, AB, Freeman, M, Kong, XF, Schipani, E, Richards, J, et al.. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 1991;254:1024\u20136. https:\/\/doi.org\/10.1126\/SCIENCE.1658941.","DOI":"10.1126\/science.1658941"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_003","doi-asserted-by":"crossref","unstructured":"Gardella, TJ, Axelrod, D, Rubin, D, Keutmann, HT, Potts, JT, Kronenberg, HM, et al.. Mutational analysis of the receptor-activating region of human parathyroid hormone. J Biol Chem 1991;266:13141\u20136. https:\/\/doi.org\/10.1016\/s0021-9258(18)98816-2.","DOI":"10.1016\/S0021-9258(18)98816-2"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_004","doi-asserted-by":"crossref","unstructured":"Pfister, MF, Ruf, I, Stange, G, Ziegler, U, Lederer, E, Biber, J, et al.. Parathyroid hormone leads to the lysosomal degradation of the renal type II Na\/Pi cotransporter. Proc Natl Acad Sci 1998;95:1909\u201314. https:\/\/doi.org\/10.1073\/pnas.95.4.1909.","DOI":"10.1073\/pnas.95.4.1909"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_005","doi-asserted-by":"crossref","unstructured":"Naylor, SL, Sakaguchi, AY, Szoka, P, Hendy, GN, Kronenberg, HM, Rich, A, et al.. Human parathyroid hormone gene (PTH) is on short arm of chromosome 11. Somat Cell Genet 1983;9:609\u201316. https:\/\/doi.org\/10.1007\/bf01574261.","DOI":"10.1007\/BF01574261"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_006","doi-asserted-by":"crossref","unstructured":"Habener, JF, Rosenblatt, M, Kemper, B, Kronenberg, HM, Rich, A, Potts, JT. Pre-proparathyroid hormone; amino acid sequence, chemical synthesis, and some biological studies of the precursor region. Proc Natl Acad Sci USA 1978;75:2616\u201320. https:\/\/doi.org\/10.1073\/pnas.75.6.2616.","DOI":"10.1073\/pnas.75.6.2616"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_007","doi-asserted-by":"crossref","unstructured":"Arnold, A, Horst, SA, Gardella, TJ, Baba, H, Levine, MA, Kronenberg, HM. Mutation of the signal peptide-encoding region of the preproparathyroid hormone gene in familial isolated hypoparathyroidism. J Clin Invest 1990;86:1084\u20137. https:\/\/doi.org\/10.1172\/JCI114811.","DOI":"10.1172\/JCI114811"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_008","doi-asserted-by":"crossref","unstructured":"Segre, GV, Perkins, AS, Witters, L, Potts, JT. Metabolism of parathyroid hormone by isolated rat kupffer cells and hepatocytes. J Clin Invest 1981;67:449\u201357. https:\/\/doi.org\/10.1172\/jci110053.","DOI":"10.1172\/JCI110053"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_009","doi-asserted-by":"crossref","unstructured":"Yamashita, H, Gao, P, Cantor, T, Futata, T, Murakami, T, Uchino, S, et al.. Large carboxy-terminal parathyroid hormone (PTH) fragment with a relatively longer half-life than 1-84 PTH is secreted directly from the parathyroid gland in humans. Eur J Endocrinol 2003;149:301\u20136. https:\/\/doi.org\/10.1530\/eje.0.1490301.","DOI":"10.1530\/eje.0.1490301"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_010","doi-asserted-by":"crossref","unstructured":"D\u2019amour, P, Lazure, C, Labelle, F. Metabolism of radioiodinated carboxy-terminal fragments of bovine parathyroid hormone in normal and anephric rats. Endocrinology 1985;117:127\u201334. https:\/\/doi.org\/10.1210\/endo-117-1-127.","DOI":"10.1210\/endo-117-1-127"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_011","doi-asserted-by":"crossref","unstructured":"Kritmetapak, K, Losbanos, LA, Hines, JM, O\u2019Grady, KL, Ulmer, CZ, Vesper, HW, et al.. Chemical characterization and quantification of circulating intact PTH and PTH fragments by high-resolution mass spectrometry in chronic renal failure. Clin Chem 2021;67:843\u201353. https:\/\/doi.org\/10.1093\/clinchem\/hvab013.","DOI":"10.1093\/clinchem\/hvab013"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_012","doi-asserted-by":"crossref","unstructured":"Singh, RJ, Hines, JM, Lopez, MF, Krastins, B, Hoofnagle, a. N. Mass spectrometric immunoassay raises doubt for the existence of parathyroid hormone fragment 7\u201384. Clin Chem 2015;61:558\u201360. https:\/\/doi.org\/10.1373\/clinchem.2014.235440.","DOI":"10.1373\/clinchem.2014.235440"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_013","doi-asserted-by":"crossref","unstructured":"Farr\u00e9-Segura, J, Le Goff, C, Lukas, P, Cobraiville, G, Fillet, M, Servais, AC, et al.. Validation of an LC-MS\/MS method using solid-phase extraction for the quanti fi cation of 1-84 parathyroid hormone\u202f: toward a candidate reference measurement procedure. Clin Chem 2022;68:1399\u2013409.","DOI":"10.1093\/clinchem\/hvac135"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_014","doi-asserted-by":"crossref","unstructured":"Sneddon, WB, Magyar, CE, Willick, GE, Syme, CA, Galbiati, F, Bisello, A, et al.. Ligand-selective dissociation of activation and internalization of the parathyroid hormone (PTH) receptor: conditional efficacy of PTH peptide fragments. Endocrinology 2004;145:2815\u201323. https:\/\/doi.org\/10.1210\/en.2003-1185.","DOI":"10.1210\/en.2003-1185"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_015","doi-asserted-by":"crossref","unstructured":"Slatopolsky, E, Finch, J, Clay, P, Martin, D, Sicard, G, Singer, G, et al.. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000;58:753\u201361. https:\/\/doi.org\/10.1046\/j.1523-1755.2000.00222.x.","DOI":"10.1016\/S0085-2538(15)47156-X"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_016","doi-asserted-by":"crossref","unstructured":"Divieti, P, Inomata, N, Chapin, K, Singh, R, J\u00fcppner, H, Bringhurst, FR. Receptors for the carboxyl-terminal region of PTH(1-84) are highly expressed in osteocytic cells. Endocrinology 2001;142:916\u201325. https:\/\/doi.org\/10.1210\/en.142.2.916.","DOI":"10.1210\/endo.142.2.7955"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_017","doi-asserted-by":"crossref","unstructured":"Divieti, P, John, MR, J\u00fcppner, H, Bringhurst, FR. Human PTH- ( 7\u201384 ) inhibits bone resorption in\u00a0vitro via actions independent of the type 1 PTH\/PTHrP receptor. Endocrinology 2002;143:171\u20136. https:\/\/doi.org\/10.1210\/endo.143.1.8575.","DOI":"10.1210\/endo.143.1.8575"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_018","doi-asserted-by":"crossref","unstructured":"Kukreja, SC, D\u2019Anza, JJ, Wimbiscus, SA, Fisher, JE, McKee, RL, Caulfield, MP, et al.. Inactivation by plasma may be responsible for lack of efficacy of parathyroid hormone antagonists in hypercalcemia of malignancy. Endocrinology 1994;134:2184\u20138. https:\/\/doi.org\/10.1210\/endo.134.5.8156920.","DOI":"10.1210\/endo.134.5.8156920"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_019","doi-asserted-by":"crossref","unstructured":"Murray, TM, Rao, LG, Muzaffar, SA, Ly, H. Human parathyroid hormone carboxyterminal peptide (53\u201384) stimulates alkaline phosphatase activity in dexamethasone-treated rat osteosarcoma cells in\u00a0vitro. Endocrinology 1989;124:1097\u20139. https:\/\/doi.org\/10.1210\/endo-124-2-1097.","DOI":"10.1210\/endo-124-2-1097"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_020","doi-asserted-by":"crossref","unstructured":"Sutherland, MK, Rao, LG, Wylie, JN, Gupta, A, Ly, H, Sodek, J, et al.. Carboxyl-terminal parathyroid hormone peptide (53\u201384) elevates alkaline phosphatase and osteocalcin mRNA levels in SaOS-2 cells. J Bone Miner Res 2009;9:453\u20138. https:\/\/doi.org\/10.1002\/jbmr.5650090403.","DOI":"10.1002\/jbmr.5650090403"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_021","doi-asserted-by":"crossref","unstructured":"Lippi, G, Guidi, GC, Mattiuzzi, C, Plebani, M. Preanalytical variability: the dark side of the moon in laboratory testing. Clin Chem Lab Med 2006;44:358\u201365. https:\/\/doi.org\/10.1515\/CCLM.2006.073.","DOI":"10.1515\/CCLM.2006.073"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_022","doi-asserted-by":"crossref","unstructured":"Lippi, G, Blanckaert, N, Bonini, P, Green, S, Kitchen, S, Palicka, V, et al.. Causes, consequences, detection, and prevention of identification errors in laboratory diagnostics. Clin Chem Lab Med 2009;47:143\u201353. https:\/\/doi.org\/10.1515\/CCLM.2009.045.","DOI":"10.1515\/CCLM.2009.045"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_023","doi-asserted-by":"crossref","unstructured":"Lippi, G, Becan-McBride, K, Beh\u00falov\u00e1, D, Bowen, RA, Church, S, Delanghe, J, et al.. Preanalytical quality improvement: in quality we trust. Clin Chem Lab Med 2013;51:229\u201341. https:\/\/doi.org\/10.1515\/CCLM-2012-0597.","DOI":"10.1515\/cclm-2012-0597"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_024","doi-asserted-by":"crossref","unstructured":"Lippi, G, Banfi, G, Church, S, Cornes, M, De Carli, G, Grankvist, K, et al.. Preanalytical quality improvement. In pursuit of harmony, on behalf of European federation for clinical Chemistry and laboratory medicine (EFLM) working group for preanalytical phase (WG-PRE). Clin Chem Lab Med 2015;53:357\u201370. https:\/\/doi.org\/10.1515\/CCLM-2014-1051.","DOI":"10.1515\/cclm-2014-1051"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_025","doi-asserted-by":"crossref","unstructured":"Cavalier, E, Plebani, M, Delanaye, P, Souberbielle, J-C. Considerations in parathyroid hormone testing. Clin Chem Lab Med 2015;53:1913\u20139. https:\/\/doi.org\/10.1515\/cclm-2015-0314.","DOI":"10.1515\/cclm-2015-0314"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_026","doi-asserted-by":"crossref","unstructured":"Hanon, EA, Sturgeon, CM, Lamb, EJ. Sampling and storage conditions influencing the measurement of parathyroid hormone in blood samples: a systematic review. Clin Chem Lab Med 2013;51:1925\u201341. https:\/\/doi.org\/10.1515\/cclm-2013-0315.","DOI":"10.1515\/cclm-2013-0315"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_027","doi-asserted-by":"crossref","unstructured":"Valcour, A, Zierold, C, Blocki, FA, Hawkins, DM, Martin, KJ, Rao, SD, et al.. Trueness, precision and stability of the LIAISON 1\u201384 parathyroid hormone (PTH) third-generation assay: comparison to existing intact PTH assays. Clin Chem Lab Med 2018;56:1476\u201382. https:\/\/doi.org\/10.1515\/cclm-2018-0217.","DOI":"10.1515\/cclm-2018-0217"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_028","unstructured":"ISO Guide 5725-6:1994. Accuracy (trueness and precision) of measurement methods and results\u00a0\u2014 part 6: use in practice of accuracy values; n.d."},{"key":"2023040601553319975_j_cclm-2022-0942_ref_029","unstructured":"World Health Organization. Use of anticoagulants in diagnostic laboratory investigations; 2002."},{"key":"2023040601553319975_j_cclm-2022-0942_ref_030","doi-asserted-by":"crossref","unstructured":"Schleck, ML, Souberbielle, JC, Delanaye, P, Plebani, M, Cavalier, E. Parathormone stability in hemodialyzed patients and healthy subjects: comparison on non-centrifuged EDTA and serum samples with second- and third-generation assays. Clin Chem Lab Med 2017;55:1152\u20139. https:\/\/doi.org\/10.1515\/cclm-2016-0914.","DOI":"10.1515\/cclm-2016-0914"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_031","doi-asserted-by":"crossref","unstructured":"Cavalier, E, Carlisi, A, Bekaert, AC, Rousselle, O, Chapelle, JP, Delanaye, P. New insights on the stability of the parathyroid hormone as assayed by an automated 3rd generation PTH assay. Clin Chim Acta 2012;413:353\u20134. https:\/\/doi.org\/10.1016\/j.cca.2011.09.034.","DOI":"10.1016\/j.cca.2011.09.034"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_032","doi-asserted-by":"crossref","unstructured":"Cavalier, E, Delanaye, P, Hubert, P, Krzesinski, JM, Chapelle, JP, Rozet, E. Estimation of the stability of parathyroid hormone when stored at\u00a0\u221280\u00b0C for a long period. Clin J Am Soc Nephrol 2009;4:1988\u201392. https:\/\/doi.org\/10.2215\/CJN.03970609.","DOI":"10.2215\/CJN.03970609"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_033","doi-asserted-by":"crossref","unstructured":"Cavalier, E, Delanaye, P, Carlisi, A, Krzesinski, JM, Chapelle, JP. Stability of intact parathyroid hormone in samples from hemodialysis patients. Kidney Int 2007;72:370\u20132. https:\/\/doi.org\/10.1038\/sj.ki.5002363.","DOI":"10.1038\/sj.ki.5002363"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_034","doi-asserted-by":"crossref","unstructured":"Vulpio, C, Bossola, M, Speranza, D, Zuppi, C, Luciani, G, Di Stasio, E. Influence of blood sampling site on intact parathyroid hormone concentrations in hemodialysis patients. Clin Chem 2010;56:489\u201390. https:\/\/doi.org\/10.1373\/clinchem.2009.136754.","DOI":"10.1373\/clinchem.2009.136754"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_035","doi-asserted-by":"crossref","unstructured":"Morris, HA, Eastell, R, Jorgensen, NR, Cavalier, E, Vasikaran, S, Chubb, SAP, et al.. IFCC-IOF working group for standardisation of bone marker assays (WG-BMA), clinical usefulness of bone turnover marker concentrations in osteoporosis. Clin Chim Acta 2017;467:34\u201341. https:\/\/doi.org\/10.1016\/j.cca.2016.06.036.","DOI":"10.1016\/j.cca.2016.06.036"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_036","doi-asserted-by":"crossref","unstructured":"Ginsberg, C, Miller, LM, Ofsthun, N, Dalrymple, LS, Ix, JH. Differences in phosphate and parathyroid hormone concentrations over the day among patients on hemodialysis. J Am Soc Nephrol 2022;33:2087\u201393. https:\/\/doi.org\/10.1681\/ASN.2021111493.","DOI":"10.1681\/ASN.2021111493"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_037","doi-asserted-by":"crossref","unstructured":"Samuels, MH, Veldhuis, JD, Kramer, P, Urban, RJ, Bauer, R, Mundy, GR. Episodic secretion of parathyroid hormone in postmenopausal women: assessment by deconvolution analysis and approximate entropy. J Bone Miner Res 1997;12:616\u201323. https:\/\/doi.org\/10.1359\/jbmr.1997.12.4.616.","DOI":"10.1359\/jbmr.1997.12.4.616"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_038","doi-asserted-by":"crossref","unstructured":"Cavalier, E, Delanaye, P, Moranne, O. Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making. Am J Kidney Dis 2013;61:847\u20138. https:\/\/doi.org\/10.1053\/j.ajkd.2012.12.013.","DOI":"10.1053\/j.ajkd.2012.12.013"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_039","doi-asserted-by":"crossref","unstructured":"Bottani, M, Banfi, G, Guerra, E, Locatelli, M, Aarsand, AK, Co\u015fkun, A, et al.. European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates for serum biointact parathyroid hormone based on weekly samplings from 91 healthy participants. Ann Transl Med 2020;8:855. https:\/\/doi.org\/10.21037\/ATM-19-4498.","DOI":"10.21037\/atm-19-4498"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_040","doi-asserted-by":"crossref","unstructured":"Guillemant, J, Cabrol, S, Allemandou, A, Peres, G, Guillemant, S. Vitamin D-dependent seasonal variation in growing male adolescents. Bone 1995;17:513\u20136. https:\/\/doi.org\/10.1016\/8756-3282(95)00401-7.","DOI":"10.1016\/8756-3282(95)00401-7"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_041","doi-asserted-by":"crossref","unstructured":"Nevo-Shor, A, Kogan, S, Joshua, BZ, Bahat-Dinur, A, Novack, V, Fraenkel, M. Seasonal changes in serum calcium, PTH and vitamin D levels in patients with primary hyperparathyroidism. Bone 2016;89:59\u201363. https:\/\/doi.org\/10.1016\/j.bone.2016.05.012.","DOI":"10.1016\/j.bone.2016.05.012"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_042","doi-asserted-by":"crossref","unstructured":"Cong, E, Walker, MD, Kepley, A, Zhang, C, McMahon, DJ, Silverberg, SJ. Seasonal variability in vitamin D levels No longer detectable in primary hyperparathyroidism. J Clin Endocrinol Metab 2015;100:3452\u20139. https:\/\/doi.org\/10.1210\/JC.2015-2105.","DOI":"10.1210\/JC.2015-2105"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_043","doi-asserted-by":"crossref","unstructured":"Bilezikian, JP, Brandi, ML, Eastell, R, Silverberg, SJ, Udelsman, R, Marcocci, C, et al.. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J Clin Endocrinol Metab 2014;99:3561\u20139. https:\/\/doi.org\/10.1210\/jc.2014-1413.","DOI":"10.1210\/jc.2014-1413"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_044","doi-asserted-by":"crossref","unstructured":"Berson, SA, Yalow, RS, Aurbach, GD, Potts, JT. Immunoassay of bovine and human parathyroid hormone. Proc Natl Acad Sci 1963;49:613\u20137. https:\/\/doi.org\/10.1073\/pnas.49.5.613.","DOI":"10.1073\/pnas.49.5.613"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_045","doi-asserted-by":"crossref","unstructured":"Nussbaum, SR, Zahradnik, RJ, Lavigne, JR, Brennan, GL, Nozawa-Ung, K, Kim, LY, et al.. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987;33:1364\u20137. https:\/\/doi.org\/10.1093\/clinchem\/33.8.1364.","DOI":"10.1093\/clinchem\/33.8.1364"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_046","doi-asserted-by":"crossref","unstructured":"Quarles, LD, Lobaugh, B, Murphy, G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992;75:145\u201350. https:\/\/doi.org\/10.1210\/jcem.75.1.1619003.","DOI":"10.1210\/jcem.75.1.1619003"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_047","doi-asserted-by":"crossref","unstructured":"Wang, M, Hercz, G, Sherrard, DJ, Maloney, NA, Segre, GV, Pei, Y. Relationship between intact 1\u201384 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995;26:836\u201344. https:\/\/doi.org\/10.1016\/0272-6386(95)90453-0.","DOI":"10.1016\/0272-6386(95)90453-0"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_048","doi-asserted-by":"crossref","unstructured":"Lepage, R, Roy, L, Brossard, JH, Rousseau, L, Dorais, C, Lazure, C, et al.. A non-(1\u201384) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998;44:805\u20139. https:\/\/doi.org\/10.1093\/clinchem\/44.4.805.","DOI":"10.1093\/clinchem\/44.4.805"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_049","doi-asserted-by":"crossref","unstructured":"John, MR, Goodman, WG, Ping, G, Cantor, T, Salusky, IB, Juppner, H. A Novel Immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999;84:4287\u201390. https:\/\/doi.org\/10.1210\/jcem.84.11.6236.","DOI":"10.1210\/jcem.84.11.6236"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_050","doi-asserted-by":"crossref","unstructured":"Sturgeon, CM, Sprague, S, Almond, A, Cavalier, E, Fraser, WD, Algeciras-Schimnich, A, et al.. Perspective and priorities for improvement of parathyroid hormone (PTH) measurement\u00a0\u2013 a view from the IFCC Working Group for PTH. Clin Chim Acta 2017;467:42\u20137. https:\/\/doi.org\/10.1016\/j.cca.2016.10.016.","DOI":"10.1016\/j.cca.2016.10.016"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_051","doi-asserted-by":"crossref","unstructured":"Kumar, V, Barnidge, DR, Chen, LS, Twentyman, JM, Cradic, KW, Grebe, SK, et al.. Quantification of serum 1\u201384 parathyroid hormone in patients with hyperparathyroidism by immunocapture in\u00a0situ digestion liquid chromatography-tandem mass spectrometry. Clin Chem 2010;56:306\u201313. https:\/\/doi.org\/10.1373\/clinchem.2009.134643.","DOI":"10.1373\/clinchem.2009.134643"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_052","doi-asserted-by":"crossref","unstructured":"Lopez, MF, Rezai, T, Sarracino, DA, Prakash, A, Krastins, B, Athanas, M, et al.. Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin Chem 2010;56:281\u201390. https:\/\/doi.org\/10.1373\/clinchem.2009.137323.","DOI":"10.1373\/clinchem.2009.137323"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_053","doi-asserted-by":"crossref","unstructured":"Rubin, MR, Silverberg, SJ, D\u2019Amour, P, Brossard, JH, Rousseau, L, Sliney, J, et al.. An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1\u201384) is overproduced in parathyroid carcinoma. Clin Chem 2007;53:1470\u20136. https:\/\/doi.org\/10.1373\/clinchem.2007.085506.","DOI":"10.1373\/clinchem.2007.085506"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_054","doi-asserted-by":"crossref","unstructured":"Cavalier, E, Daly, AF, Betea, D, Pruteanu-Apetrii, PN, Delanaye, P, Stubbs, P, et al.. The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. J Clin Endocrinol Metab 2010;95:3745\u20139. https:\/\/doi.org\/10.1210\/jc.2009-2791.","DOI":"10.1210\/jc.2009-2791"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_055","doi-asserted-by":"crossref","unstructured":"R\u00e4kel, A, Brossard, JH, Patenaude, JV, Albert, C, Nassif, E, Cantor, T, et al.. Overproduction of an amino-terminal form of PTH distinct from human PTH(1\u201384) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery. Clin Endocrinol 2005;62:721\u20137. https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02286.x.","DOI":"10.1111\/j.1365-2265.2005.02286.x"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_056","doi-asserted-by":"crossref","unstructured":"Souberbielle, JC, Friedlander, G, Cormier, C. Practical considerations in PTH testing. Clin Chim Acta 2006;366:81\u20139. https:\/\/doi.org\/10.1016\/j.cca.2005.10.010.","DOI":"10.1016\/j.cca.2005.10.010"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_057","doi-asserted-by":"crossref","unstructured":"D\u2019Amour, P, Brossard, JH, Rousseau, L, Roy, L, Gao, P, Cantor, T. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1\u201384) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 2003;49:2037\u201344. https:\/\/doi.org\/10.1373\/clinchem.2003.021592.","DOI":"10.1373\/clinchem.2003.021592"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_058","doi-asserted-by":"crossref","unstructured":"Schulte, KM, Talat, N. Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol 2012;8:612\u201322. https:\/\/doi.org\/10.1038\/nrendo.2012.102.","DOI":"10.1038\/nrendo.2012.102"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_059","doi-asserted-by":"crossref","unstructured":"Caron, P, Maiza, JC, Renaud, C, Cormier, C, Barres, BH, Souberbielle, JC. High 3rd generation\/2nd generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of 3rg generation\/2nd generation PTH ratio in patients with primary hyperparathyroidism. Clin Endocrinol 2008;70:533\u20138. https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03408.x.","DOI":"10.1111\/j.1365-2265.2008.03408.x"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_060","doi-asserted-by":"crossref","unstructured":"Hocher, B, Yin, L. Why current PTH assays mislead clinical decision making in patients with secondary hyperparathyroidism. Nephron 2017;136:137\u201342. https:\/\/doi.org\/10.1159\/000455289.","DOI":"10.1159\/000455289"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_061","doi-asserted-by":"crossref","unstructured":"Himmelfarb, J, Stenvinkel, P, Ikizler, TA, Hakim, RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524\u201338. https:\/\/doi.org\/10.1046\/J.1523-1755.2002.00600.X.","DOI":"10.1046\/j.1523-1755.2002.00600.x"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_062","doi-asserted-by":"crossref","unstructured":"Hocher, B, Armbruster, FP, Stoeva, S, Reichetzeder, C, Gr\u00f6n, HJ, Lieker, I, et al.. Measuring parathyroid hormone (PTH) in patients with oxidative stress\u00a0\u2013 do we need a fourth generation parathyroid hormone assay? PLoS One 2012;7:e40242. https:\/\/doi.org\/10.1371\/journal.pone.0040242.","DOI":"10.1371\/journal.pone.0040242"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_063","doi-asserted-by":"crossref","unstructured":"Lu, YP, Zeng, S, Chu, C, Hasan, AA, Slowinski, T, Yin, LH, et al.. Non-oxidized PTH (n-oxPTH) is associated with graft loss in kidney transplant recipients. Clin Chim Acta 2020;508:92\u20137. https:\/\/doi.org\/10.1016\/J.CCA.2020.05.022.","DOI":"10.1016\/j.cca.2020.05.022"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_064","doi-asserted-by":"crossref","unstructured":"Hocher, B, Zeng, S. Need for better PTH assays for clinical research and patient treatment. Clin Chem Lab Med 2017;56:13\u20135. https:\/\/doi.org\/10.1515\/cclm-2017-0617.","DOI":"10.1515\/cclm-2017-0617"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_065","doi-asserted-by":"crossref","unstructured":"Seiler-Mussler, S, Limbach, AS, Emrich, IE, Pickering, JW, Roth, HJ, Fliser, D, et al.. Association of nonoxidized parathyroid hormone with cardiovascular and kidney disease outcomes in chronic kidney disease. Clin J Am Soc Nephrol 2018;13:569\u201376. https:\/\/doi.org\/10.2215\/CJN.06620617.","DOI":"10.2215\/CJN.06620617"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_066","doi-asserted-by":"crossref","unstructured":"Ursem, SR, Heijboer, AC, D\u2019Haese, PC, Behets, GJ, Cavalier, E, Vervloet, MG, et al.. Non-oxidized parathyroid hormone (PTH) measured by current method is not superior to total PTH in assessing bone turnover in chronic kidney disease. Kidney Int 2021;99:1173\u20138. https:\/\/doi.org\/10.1016\/j.kint.2020.12.024.","DOI":"10.1016\/j.kint.2020.12.024"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_067","doi-asserted-by":"crossref","unstructured":"KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis. Evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2017;7:1\u201359. https:\/\/doi.org\/10.1016\/j.kisu.2017.04.001.","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_068","doi-asserted-by":"crossref","unstructured":"Touvier, M, Deschasaux, M, Montourcy, M, Sutton, A, Charnaux, N, Kesse-Guyot, E, et al.. Interpretation of plasma PTH concentrations according to 25OHD status, gender, age, weight status, and calcium intake: importance of the reference values. J Clin Endocrinol Metab 2014;99:1196\u2013203. https:\/\/doi.org\/10.1210\/jc.2013-3349.","DOI":"10.1210\/jc.2013-3349"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_069","doi-asserted-by":"crossref","unstructured":"Souberbielle, JC, Fayol, V, Sault, C, Lawson-Body, E, Kahan, A, Cormier, C. Assay-specific decision limits for two new automated parathyroid hormone and 25-hydroxyvitamin D assays. Clin Chem 2005;51:395\u2013400. https:\/\/doi.org\/10.1373\/clinchem.2004.037606.","DOI":"10.1373\/clinchem.2004.037606"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_070","doi-asserted-by":"crossref","unstructured":"Cavalier, E, Delanaye, P, Vranken, L, Bekaert, AC, Carlisi, A, Chapelle, JP, et al.. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol Dial Transplant 2011;27:1950\u20136. https:\/\/doi.org\/10.1093\/ndt\/gfr535.","DOI":"10.1093\/ndt\/gfr535"},{"key":"2023040601553319975_j_cclm-2022-0942_ref_071","doi-asserted-by":"crossref","unstructured":"Moe, SM, Drueke, TB. For the K.W. Group, KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD). Kidney Int 2009;76:S1\u201328. https:\/\/doi.org\/10.1038\/ki.2009.188.","DOI":"10.1038\/ki.2009.188"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-0942\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-0942\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T02:20:37Z","timestamp":1680747637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-0942\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":71,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,10,27]]},"published-print":{"date-parts":[[2023,4,25]]}},"alternative-id":["10.1515\/cclm-2022-0942"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2022-0942","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,16]]}}}